Safety of ceftriaxone in paediatrics: a systematic review
Open Access
- 6 March 2020
- journal article
- review article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 105 (10) , 981-985
Abstract
Objective To determine the safety of ceftriaxone in paediatric patients and systematically evaluate the categories and incidences of adverse drug reactions (ADRs) of ceftriaxone in paediatric patients. Methods We performed a systematic search in Medline, PubMed, Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, International Pharmaceutical Abstracts and bibliographies of relevant articles up to December 2018 for all types of studies that assessed the safety of ceftriaxone in paediatric patients aged ≤18 years. Results 112 studies met the inclusion criteria involving 5717 paediatric patients who received ceftriaxone and reported 1136 ADRs. The most frequent ADRs reported in prospective studies were gastrointestinal (GI) disorders (37.4 %, 292/780), followed by hepatobiliary disorders (24.6%, 192/780). Serious ADRs leading to withdrawal or discontinuation of ceftriaxone were reported in 86 paediatric patients. Immune haemolytic anaemia (34.9%, 30/86) and biliary pseudolithiasis (26.7%, 23/86) were the two major causes. Haemolytic anaemia following intravenous ceftriaxone led to death in 11 children whose primary disease was sickle cell disease. Almost all biliary pseudolithiasis are reversible. However, the incidence was high affecting one in five paediatric patients (20.7%). Conclusions GI ADRs are the most common toxicity of ceftriaxone in paediatric patients. Immune haemolytic anaemia and biliary pseudolithiasis are the most serious ADRs and the major reasons for discontinuation of ceftriaxone. Immune haemolytic anaemia is more likely in children with sickle cell disease and may cause death. Ceftriaxone should be used with caution in children with sickle cell disease. Trial registration number CRD42017055428Keywords
Funding Information
- Key Program of Science and Technology Agency, Sichuan Province (No. 2017JY0067)
This publication has 20 references indexed in Scilit:
- Antibiotics for Post-Tonsillectomy Morbidity: Comparative Analysis of a Single Institutional ExperienceJournal of Clinical Medicine Research, 2016
- Ceftriaxone-Induced Immune Hemolytic AnemiaAnnals of Pharmacotherapy, 2014
- Urinary Sludge Caused by Ceftriaxone in a Young BoyPediatric Reports, 2012
- Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance CentreJournal of Clinical Pharmacy and Therapeutics, 2011
- Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infectionInternational Journal of Antimicrobial Agents, 2009
- Ceftriaxone associated nephrolithiasis: a prospective study in 284 childrenPediatric Nephrology, 2007
- CeftriaxoneDrugs, 2002
- Pharmacokinetics and Pharmacodynamics of Cephalosporins in Cerebrospinal FluidClinical Pharmacokinetics, 2000
- Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemiaThe Journal of Pediatrics, 1995
- A Comparison of Ceftriaxone and Cefuroxime for the Treatment of Bacterial Meningitis in ChildrenNew England Journal of Medicine, 1990